Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
In this study, efficacy and safety of 2 regimens that combine the CD3-CD20 T cell engager epcoritamab with venetoclax will be tested in relapsed/refractory CLL and SLL patients. The trial starts with phase I part to establish the recommended dose level (RDL) of epcoritamab in the combination with venetoclax for the phase II trial.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nawrotowy lub oporny ChPLL/ChSLL po co najmniej jednym leczeniu
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (skala 0-2)
- •Jeśli wcześniej pacjent otrzymywał venetoclax, musi minąć co najmniej 24 miesiące od końca leczenia i nie może dojść do pogorszenia w trakcie venetoclaxu
- •Prawidłowe wyniki krwi: hemoglobina powyżej normy, liczba neutrofili powyżej 1000/μL, płytki krwi powyżej 30 000/μL
- •Prawidłowa funkcja nerek: klirens kreatyniny co najmniej 50 ml/min
- •Prawidłowa funkcja wątroby: prawidłowe enzymy wątrobowe i bilirubina
- •Ujemne wyniki testów na wirusy zapalenia wątroby B i C
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (29)
AU-Melbourne-ALFRED
Melbourne, Australia
AU-Melbourne-MONASH
Melbourne, Australia
AU-Melbourne-SVHM
Melbourne, Australia
BE-Antwerpen-ZNASTUIVENBERG
Antwerp, Belgium
BE-Roeselare-AZDELTA
Roeselare, Belgium
DK-Aalborg-ALBOGUH
Aalborg, Denmark
DK-Copenhagen-RIGSHOSPITALET
Copenhagen, Denmark
DK-Odense-OUH
Odense, Denmark
DE-Berlin-HELIOSBERLINBUCH
Berlin, Germany
DE-Köln-UKKOELN
Cologne, Germany
DE-Freiburg-UNIKLINIKFREIBURG
Freiburg im Breisgau, Germany
DE-Greifswald-UNIGREIFSWALD
Greifswald, Germany
DE-Halle-UMH
Halle, Germany
DE-Kiel-UKSH
Kiel, Germany
DE-Munster-GEMEINSCHAFTSPRAXIS
Münster, Germany
DE-Stuttgart-RBK
Stuttgart, Germany
DE-Ulm-UNIKLINKULM
Ulm, Germany
NL-Den Bosch-JBZ
's-Hertogenbosch, Netherlands
NL-Alkmaar-NWZ
Alkmaar, Netherlands
NL-Amersfoort-MEANDERMC
Amersfoort, Netherlands
NL-Amsterdam-AMC
Amsterdam, Netherlands
NL-Dordrecht-ASZ
Dordrecht, Netherlands
NL-Ede-ZGV
Ede, Netherlands
NL-Eindhoven-CATHARINA
Eindhoven, Netherlands
NL-Groningen-UMCG
Groningen, Netherlands
NL-Leeuwarden-MCL
Leeuwarden, Netherlands
NL-Den Haag-HAGA
The Hague, Netherlands
NL-Tilburg-ETZ
Tilburg, Netherlands
NL-Utrecht-UMCUTRECHT
Utrecht, Netherlands
Trial contact
Arnon Kater
Mark-David Levin
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.